Osteoporosis Peptide Drug Delivered by Skin Patch Shows Promise in Early Trial
A transdermal microneedle patch delivering the osteoporosis drug abaloparatide was successfully self-administered by all 22 women in the trial, boosting bone formation markers by 64% over 29 days.
Quick Facts
What This Study Found
A transdermal microneedle patch delivering abaloparatide (an osteoporosis peptide drug) was successfully self-administered by all 22 postmenopausal women enrolled in the trial, with a 99.7% success rate on first application. The patch delivered consistent drug levels over 29 days, with bone formation marker s-PINP increasing by 45.4% at Day 15 and 64.4% at Day 29 — similar to results seen with the standard subcutaneous injection.
The patch was applied to the thigh for 5 minutes daily at a 300 μg dose. Drug absorption was rapid (peak levels reached in about 20 minutes). Side effects were mostly mild application-site reactions (redness, pain, swelling), and no one dropped out due to adverse events. Patient acceptability scored approximately 4.5 out of 5.
Key Numbers
n=22 · 300 μg daily dose · 5-min application · s-PINP +45.4% Day 15, +64.4% Day 29 · Tmax 0.33 h · Cmax 447 pg/mL · 99.7% self-admin success · 4.5/5 acceptability · 29 days · mean age 65.2 years
How They Did This
Single-arm, open-label Phase 1b clinical trial. 22 healthy postmenopausal women (ages 50-85) with low bone mineral density were trained to self-administer the abaloparatide transdermal patch to the thigh daily for 29 days. Pharmacokinetics, bone formation markers, patient experience, and safety were measured.
Why This Research Matters
Abaloparatide currently requires daily subcutaneous injections, which many osteoporosis patients find burdensome and which limits treatment adherence. A painless transdermal patch that patients can apply themselves could dramatically improve how many people actually stick with treatment — potentially reducing fractures in a population where medication adherence is notoriously poor.
The Bigger Picture
Transdermal microneedle delivery is one of the most promising technologies for making peptide drugs more patient-friendly. If the abaloparatide patch succeeds in larger trials, it would prove that osteoporosis patients don't have to choose between effective treatment and daily needle injections. The approach could also be adapted for other injectable peptide drugs, potentially transforming adherence across multiple therapeutic areas.
What This Study Doesn't Tell Us
Small sample size (n=22) and single-arm design without a comparator group or placebo control. The 29-day duration is too short to assess fracture risk reduction or long-term BMD changes. Participants were trained and supervised, which may inflate self-administration success rates compared to real-world use.
Questions This Raises
- ?Will the bone formation effects seen in 29 days translate to meaningful fracture risk reduction in longer Phase 2/3 trials?
- ?How does long-term skin tolerability compare when the patch is used for months or years rather than 29 days?
- ?Could this transdermal microstructure technology be applied to deliver other peptide drugs like teriparatide or GLP-1 agonists?
Trust & Context
- Key Stat:
- 64.4% increase Bone formation marker s-PINP increased by 64.4% after 29 days of transdermal patch delivery — comparable to results from standard subcutaneous injection
- Evidence Grade:
- This is a Phase 1b clinical trial with a small sample (n=22) and no control group. While results are encouraging, larger controlled trials are needed to confirm efficacy and safety before this delivery method can be approved.
- Study Age:
- Published in 2021 in Clinical Drug Investigation. The abaloparatide transdermal system continues in clinical development, making these early results directly relevant to the current pipeline.
- Original Title:
- Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
- Published In:
- Clinical drug investigation, 41(3), 277-285 (2021)
- Authors:
- Miller, Paul D, Troy, Steven, Weiss, Richard J, Annett, Miriam, Schense, Jason, Williams, Setareh A, Mitlak, Bruce
- Database ID:
- RPEP-05610
Evidence Hierarchy
Frequently Asked Questions
How does the abaloparatide skin patch work?
The patch uses solid microstructures — tiny projections smaller than a needle — that penetrate the outer layer of skin to deliver abaloparatide intradermally. You apply it to your thigh for 5 minutes and then remove it. The drug reaches peak blood levels in about 20 minutes.
Is the transdermal abaloparatide patch available yet?
Not yet — this was a Phase 1b trial testing whether the patch works and is tolerable. The results were positive enough to support continued development, but larger clinical trials are needed before FDA approval. The standard injectable form (Tymlos) is currently available for osteoporosis treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05610APA
Miller, Paul D; Troy, Steven; Weiss, Richard J; Annett, Miriam; Schense, Jason; Williams, Setareh A; Mitlak, Bruce. (2021). Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.. Clinical drug investigation, 41(3), 277-285. https://doi.org/10.1007/s40261-021-01008-7
MLA
Miller, Paul D, et al. "Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.." Clinical drug investigation, 2021. https://doi.org/10.1007/s40261-021-01008-7
RethinkPeptides
RethinkPeptides Research Database. "Phase 1b Evaluation of Abaloparatide Solid Microstructured T..." RPEP-05610. Retrieved from https://rethinkpeptides.com/research/miller-2021-phase-1b-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.